Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Azurrx Biopharma Inc (AZRX)

Azurrx Biopharma Inc (AZRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 20,630
  • Shares Outstanding, K 28,503
  • Annual Sales, $ 0 K
  • Annual Income, $ -15,180 K
  • 60-Month Beta 1.86
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade AZRX with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.54
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 11/12/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -0.12
  • Number of Estimates 4
  • High Estimate -0.08
  • Low Estimate -0.14
  • Prior Year -0.17
  • Growth Rate Est. (year over year) +29.41%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6501 +9.37%
on 09/25/20
0.8649 -17.79%
on 08/31/20
-0.1291 (-15.37%)
since 08/28/20
3-Month
0.6501 +9.37%
on 09/25/20
1.3000 -45.31%
on 08/12/20
-0.1951 (-21.53%)
since 06/30/20
52-Week
0.3709 +91.70%
on 03/12/20
1.9383 -63.32%
on 01/10/20
+0.1110 (+18.50%)
since 09/30/19

Most Recent Stories

More News
AzurRx BioPharma Announces Two Abstracts Accepted for Presentation at the 2020 North American Cystic Fibrosis Virtual Conference

Abstracts to Focus on:

AZRX : 0.7110 (-1.77%)
LD Micro - 360 Companies Set to Present this Week

LD Micro today announced the final list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online.

ACRX : 1.4200 (-0.70%)
ACER : 2.88 (-7.99%)
ACU : 23.03 (+0.78%)
AT.VN : 1.610 (-0.62%)
AEY : 1.9200 (+1.59%)
ADIL : 2.23 (-26.40%)
ADTX : 1.9500 (+4.84%)
ADXS : 0.4100 (-2.61%)
AEHR : 1.3900 (-0.71%)
AIM : 2.15 (+1.42%)
AIRI : 1.2200 (-3.17%)
ALIM : 4.86 (-6.18%)
ALJJ : 0.7251 (+0.29%)
ALLT : 9.10 (-1.62%)
ARCT : 42.90 (+0.40%)
AREC : 1.5000 (-1.32%)
AMS : 1.8100 (-7.65%)
ANVS : 4.81 (+0.84%)
APEN : 1.6900 (+1.20%)
APM : 2.68 (-43.70%)
AQMS : 0.9110 (-1.47%)
AQB : 4.48 (-1.54%)
ARTL : 0.9926 (+11.53%)
ARHH : 0.8980 (+4.77%)
ATOM : 10.45 (-0.95%)
ATOS : 2.42 (-3.97%)
AUTO : 3.14 (-1.57%)
AYRO : 2.96 (-6.62%)
AZRX : 0.7110 (-1.77%)
BELFA : 11.71 (+4.30%)
BCDA : 2.27 (-2.16%)
BIOC : 4.41 (-2.65%)
BHTG : 1.4500 (+18.85%)
BIOL : 0.2751 (+0.77%)
BKEP : 1.5400 (-3.14%)
ATDS : 0.0091 (-3.19%)
ASUR : 7.55 (+0.80%)
BEER.VN : 0.055 (+10.00%)
ANY : 2.47 (-4.63%)
AzurRx BioPharma to Present at the 2020 H.C. Wainwright 22nd Annual Global Investment Conference (September 14) and the LD 500 Virtual Conference (September 4)

AzurRx BioPharma, Inc. (NASDAQ:AZRX) ("AzurRx" or the "Company"), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced that it...

AZRX : 0.7110 (-1.77%)
Worldwide Chronic Pancreatitis (CP) Market Analysis 2017-2030 - Epidemiology, Therapies, Drugs, Players, Unmet Needs

, /PRNewswire/ -- The drug pipelines has been added to offering.

AZRX : 0.7110 (-1.77%)
AzurRx BioPharma Initiates European Arm of Phase 2b OPTION 2 Clinical Trial of MS1819 in Cystic Fibrosis

-- Three clinical trial sites activated in Poland, with patient screening initiated

AZRX : 0.7110 (-1.77%)
AzurRx BioPharma Announces First Patients Dosed in Phase 2b OPTION 2 Clinical Trial of MS1819 in Cystic Fibrosis

-- First three patients enrolled in dose escalation trial using delayed-release enteric capsules

AZRX : 0.7110 (-1.77%)
AzurRx BioPharma CEO Issues Clarifying Statement to Shareholders

AzurRx BioPharma, Inc. ("AzurRx" or the "Company") (NASDAQ: AZRX), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today issued the following...

AZRX : 0.7110 (-1.77%)
AzurRx BioPharma Announces Positive Interim Data From First Patient Cohort in Phase 2 Clinical Trial of MS1819 in Combination with PERT Therapy in the Treatment of Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency

Management to discuss the interim results on call scheduled for today, August 11, 2020, at 4:30 p.m. Eastern Time

AZRX : 0.7110 (-1.77%)
LD Micro Announces Preliminary List of Presenters for the LD 500

LD Micro today announced the initial list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online.

ACER : 2.88 (-7.99%)
ACU : 23.03 (+0.78%)
AEY : 1.9200 (+1.59%)
ADIL : 2.23 (-26.40%)
ADXS : 0.4100 (-2.61%)
AEHR : 1.3900 (-0.71%)
AIM : 2.15 (+1.42%)
AIRI : 1.2200 (-3.17%)
KERN : 3.64 (-2.15%)
ALIM : 4.86 (-6.18%)
ALLT : 9.10 (-1.62%)
AMS : 1.8100 (-7.65%)
ANVS : 4.81 (+0.84%)
APEN : 1.6900 (+1.20%)
APM : 2.68 (-43.70%)
AQB : 4.48 (-1.54%)
ARTL : 0.9926 (+11.53%)
ARHH : 0.8980 (+4.77%)
ATOM : 10.45 (-0.95%)
ATOS : 2.42 (-3.97%)
ACU.VN : 0.145 (+3.57%)
AUTO : 3.14 (-1.57%)
AYRO : 2.96 (-6.62%)
AYTU : 1.1900 (-0.83%)
AZRX : 0.7110 (-1.77%)
BLDP : 15.10 (unch)
BELFA : 11.71 (+4.30%)
BCDA : 2.27 (-2.16%)
BIOC : 4.41 (-2.65%)
BMRA : 6.93 (-3.35%)
BSGM : 4.93 (+1.02%)
BLNK : 10.31 (+3.20%)
BKEP : 1.5400 (-3.14%)
CLBS : 1.8000 (-4.26%)
CLXT : 5.49 (-4.69%)
ASUR : 7.55 (+0.80%)
BLGO : 0.1502 (-3.03%)
AzurRx BioPharma Announces Entry into Packaging, Labeling and Distribution Agreement with Creapharm Clinical Supplies for MS1819 Clinical Trial Drug Product

AzurRx BioPharma, Inc. (NASDAQ:AZRX) ("AzurRx" or the "Company"), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced that it...

AZRX : 0.7110 (-1.77%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Strengthening short term outlook on maintaining the current direction.

See More Share

Business Summary

Azurrx Biopharma, Inc. is a biopharmaceutical company. It focused on the development of recombinant proteins for the treatment of gastrointestinal diseases and microbiome related conditions. The company's product pipeline consists of MS1819, a recombinant lipase for the treatment of exocrine pancreatic...

See More

Key Turning Points

2nd Resistance Point 0.7783
1st Resistance Point 0.7447
Last Price 0.7110
1st Support Level 0.6887
2nd Support Level 0.6663

See More

52-Week High 1.9383
Fibonacci 61.8% 1.3396
Fibonacci 50% 1.1546
Fibonacci 38.2% 0.9696
Last Price 0.7110
52-Week Low 0.3709

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar